Skip to content

ATP-TESTing following Time-observation for Enhanced PV Isolation as a Procedural Endpoint of Catheter Ablation for Paroxysmal Atrial Fibrillation (ATTEST): A Prospective Multi-Center randomized Controlled Study

ATP-TESTing following Time-observation for Enhanced PV Isolation as a Procedural Endpoint of Catheter Ablation for Paroxysmal Atrial Fibrillation (ATTEST): A Prospective Multi-Center randomized Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17011695
Enrollment
Unknown
Registered
2017-06-19
Start date
2016-08-01
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

A:10mins observation post PVI
B:10mins observation post PVI + ATP testing
C:60mins observation post PVI + ATP testing

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Patient aged 18 to 75 years; 2) Patient with paroxysmal AF; 3) Patient with symptomatic AF that is refractory to at least one antiarrhythmic medication; 4) Patient undergoes a first-time ablation procedure for AF; 5) Patient to able to provide written Informed consent prior to any study related procedure.

Exclusion criteria

Exclusion criteria: 1) Patient unable to comply with the follow-up schedule; 2) Patient has a history of previous AF ablation; 3) Patient has thrombosis in LA before the procedure; 4) Patient's AF is due to reversible causes, such as but not limited to hyperthyroidism; 5) Patient who has previous cardiac surgery; 6) Patient who has = moderate valvular heart disease; 7) Patient who has actively ischemic heart disease; 8) Patient who has hypertrophic cardiomyopathy; 9) Patient who has chronic obstructive lung disease; 10) Left Ventricular Ejection Fraction < 45%; 11) Female patient who is pregnant or is going to be pregnant within 1 year; 12) Patient who is contraindicated to anticoagulation, isoproterenol or ATP; 13) Patient has a life expectancy of = 2 years due to any known condition.

Design outcomes

Primary

MeasureTime frame
None-AF survival;

Countries

China

Contacts

Public ContactChenyang Jiang

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

jiangchenyangmail@163.com+86 13857190051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026